Nimotuzumab in the Management of Recurrent Endometrial Carcinoma: A Case Report.
作者信息
Rawat Shyamji
机构信息
Department of Radiotherapy, Netaji Subhash Chandra Bose Medical College and Hospital, Tilwara Road, Jabalpur, Madhya Pradesh 482003 India.
出版信息
J Obstet Gynaecol India. 2018 Oct;68(5):417-419. doi: 10.1007/s13224-017-1056-6. Epub 2017 Nov 10.
Abstract
摘要
相似文献
1
Nimotuzumab in the Management of Recurrent Endometrial Carcinoma: A Case Report.尼妥珠单抗治疗复发性子宫内膜癌：一例报告
J Obstet Gynaecol India. 2018 Oct;68(5):417-419. doi: 10.1007/s13224-017-1056-6. Epub 2017 Nov 10.
2
Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.尼妥珠单抗治疗局部晚期或转移性食管鳞癌患者的真实世界总生存。
Adv Ther. 2017 Dec;34(12):2638-2647. doi: 10.1007/s12325-017-0631-7. Epub 2017 Nov 13.
3
Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial.诱导化疗后序贯同步放化疗联合尼妥珠单抗治疗局部区域晚期鼻咽癌：一项II期临床试验的初步结果
Oncotarget. 2017 Jan 10;8(2):2457-2465. doi: 10.18632/oncotarget.13899.
4
Clinical effectiveness of 125I-seed implantation in combination with nimotuzumab therapy for the advanced oral carcinoma: preliminary results.¹²⁵I粒子植入联合尼妥珠单抗治疗晚期口腔癌的临床疗效：初步结果
Eur Rev Med Pharmacol Sci. 2014;18(21):3304-10.
5
Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.尼妥珠单抗治疗局部晚期头颈部鳞癌的药效学研究：SENDO 基金会研究。
Clin Cancer Res. 2010 Apr 15;16(8):2474-82. doi: 10.1158/1078-0432.CCR-09-3042. Epub 2010 Apr 6.
6
Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.尼妥珠单抗为不可切除的晚期头颈部鳞状细胞癌患者带来生存获益：一项针对印度患者的随机、开放标签、IIb期、为期5年的研究。
Oral Oncol. 2014 May;50(5):498-505. doi: 10.1016/j.oraloncology.2013.11.008. Epub 2014 Mar 6.
7
[The radiosensitization of nimotuzumab on CAL-27 cells after I seeds irradiation].
Shanghai Kou Qiang Yi Xue. 2016 Aug;25(4):409-413.
8
Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma.尼妥珠单抗联合化疗一线治疗晚期肺鳞癌。
Thorac Cancer. 2018 Aug;9(8):1056-1061. doi: 10.1111/1759-7714.12789. Epub 2018 Jun 19.
9
Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.尼妥珠单抗增强光动力疗法在口腔肿瘤模型中的抗肿瘤作用。
Oncotarget. 2015 May 30;6(15):13487-505. doi: 10.18632/oncotarget.3622.
10
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].尼妥珠单抗联合化疗治疗恶性胶质瘤患者
Zhonghua Zhong Liu Za Zhi. 2011 Mar;33(3):232-5.
本文引用的文献
1
Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.尼妥珠单抗为不可切除的晚期头颈部鳞状细胞癌患者带来生存获益：一项针对印度患者的随机、开放标签、IIb期、为期5年的研究。
Oral Oncol. 2014 May;50(5):498-505. doi: 10.1016/j.oraloncology.2013.11.008. Epub 2014 Mar 6.
2
Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.使用人源化抗表皮生长因子抗体尼妥珠单抗联合放射治疗和化疗治疗恶性、不可切除的上皮源性食管肿瘤。
Cancer Biol Ther. 2012 Jun;13(8):600-5. doi: 10.4161/cbt.19849. Epub 2012 Jun 1.
3
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.尼妥珠单抗（一种人源化单克隆抗表皮生长因子受体（EGFR）抗体）治疗局部晚期或转移性胰腺癌的 II 期研究。
Invest New Drugs. 2012 Jun;30(3):1138-43. doi: 10.1007/s10637-010-9619-8. Epub 2010 Dec 21.
4
Promising novel therapies for the treatment of endometrial cancer.有前景的新型疗法治疗子宫内膜癌。
Gynecol Oncol. 2010 Feb;116(2):187-94. doi: 10.1016/j.ygyno.2009.10.041. Epub 2009 Nov 10.
Zotero 插件